Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

摘要

The present invention provides uses for cyclin-dependent kinase (CDK) inhibitors (for example, GW-8510, purvalanol A) for lowering intraocular pressure by administering to a patient a therapeutically effective amount of such an agent that inhibits expression and/or signaling of CTGF.